title: Pancreatic secretory trypsin inhibitor is a major motogenic and protective factor in human breast milk.
abstract: Colostrum is the first milk produced after birth and is rich in immunoglobulins and bioactive molecules. We examined whether human colostrum and milk contained pancreatic secretory trypsin inhibitor (PSTI), a peptide of potential relevance for mucosal defense and, using in vitro and in vivo models, determined whether its presence influenced gut integrity and repair. Human milk was collected from individuals over various times from parturition and PSTI concentrations determined with the use of immunoassay. Human milk samples were analyzed for proliferation and promigratory activity (wounded monolayers) and antiapoptotic activity (caspase-3 activity) with the use of intestinal HT29 cells with or without neutralizing antibodies to PSTI and epidermal growth factor (EGF). Rats were restrained and given indomethacin to induce gastric injury. Effect of gavage with human breast milk with or without neutralizing antibodies on amount of injury were compared with animals receiving a commercial formula feed. PSTI is secreted into human milk, with colostrum containing a much higher concentration of PSTI than human milk obtained later. Human milk stimulated migration and proliferation about threefold and reduced indomethacin-induced apoptosis by about 70-80%. Sixty-five percent of the migratory effect of human milk could be removed by immunoneutralization of PSTI. PSTI worked synergistically with EGF in mediating these effects. Gastric damage in rats was reduced by about 75% in the presence of human milk and was more efficacious than the formula feed (P<0.001). Protective effects of the milk were reduced by about 60% by PSTI immunoneutralization. We concluded that PSTI is secreted into human milk at concentrations that have probable pathophysiological relevance.
authors.affiliation: Centre for Gastroenterology, Institute of Cell and Molecular Science, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, and Queen Charlotte's Hospital, Turner St., London E1 2AD, UK.
authors.forename: Tania
authors.initials: T
authors.lastname: Marchbank
authors.forename: Gillian
authors.initials: G
authors.lastname: Weaver
authors.forename: Marit
authors.initials: M
authors.lastname: Nilsen-Hamilton
authors.forename: Raymond J
authors.initials: RJ
authors.lastname: Playford
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002352:Carrier Proteins / Q000032:analysis / Q000502:physiology*; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D003126:Colostrum / Q000737:chemistry*; D019073:HT29 Cells; D006801:Humans; D007213:Indomethacin / Q000633:toxicity; D008895:Milk, Human / Q000737:chemistry*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013272:Stomach Diseases / Q000139:chemically induced / Q000517:prevention & control; D014359:Trypsin Inhibitor, Kazal Pancreatic
chemical_list: D002352:Carrier Proteins; C486642:SPINK1 protein, human; D014359:Trypsin Inhibitor, Kazal Pancreatic; D007213:Indomethacin